Traveler01

Ofatumumab Demonstrates Superiority Versus Teriflunomide in Two Head-to-Head Phase III Multiple Sclerosis StudiesCompany AnnouncementIn ASCLEPIOS I and II, ofatumumab (OMB157) met primary endpoi...

Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody-CD38Company AnnouncementGenmab signs agreement with Janssen Biotech, Inc. to collaborate exclusively on next...

July 12, 2018 5:57 AM UTCGenmab Enters Strategic Partnership with Immatics to Discover and Develop Next Generation Bispecific Cancer ImmunotherapiesCompany AnnouncementGenmab gains exclusive a...

November 8, 2017; Copenhagen, Denmark;Interim Report for the First Nine Months Ended September 30, 2017HighlightsUSD 871 million in net sales of DARZALEX (daratumumab); resulting in ...

Company AnnouncementNet sales of DARZALEX in the second quarter of 2017 totaled USD 299 millionGenmab will receive royalties on worldwide net sales from Janssen Biotech, Inc.Copenhagen, Denmar...

May 10, 2017; Copenhagen, Denmark; Interim Report for the First Quarter of 2017HighlightsUSD 255 million in net sales of DARZALEX (daratumumab); resulting in royalty income of DKK 211 ...

Company AnnouncementCopenhagen, Denmark; February 22, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today its Annual Report for 2016. Below is a summary of business progress and financial ...

Een nieuwe aanpassing van de op 22 februari te publiceren cijfers.Company AnnouncementCopenhagen, Denmark; February 6, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today that it has ...

ir.genmab.com/releasedetail.cfm?Relea...derde kwartaal Genmab...

ir.genmab.com/releasedetail.cfm?Relea...Daratumumab Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration in Combination with Standard of Care Regimens fo...

The trial is the latest in a string of successful studies of Darzalex, which JJ is co-developing with Danish biotech group Genmab, prompting Jefferies analyst Peter Welford to estimate that the d...

2,5 miljoen stuks in de eindveiling. Iemand een idee?...